Latest News and Press Releases

Loughborough, England, Aug. 01, 2019 (GLOBE NEWSWIRE) --  Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive,...

Loughborough, England , July 18, 2019 (GLOBE NEWSWIRE) --  Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable...

Loughborough, England , July 10, 2019 (GLOBE NEWSWIRE) --  Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable...

On track to submit FDA application for SugarBEAT in mid 2019 Loughborough, England , June 17, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company...

Loughborough, England, June 14, 2019 (GLOBE NEWSWIRE) --  – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable...

Loughborough,England, May 29, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and...

Loughborough, England , May 02, 2019 (GLOBE NEWSWIRE) --  – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable...

Loughborough, England , April 23, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable...

Loughborough, England , April 16, 2019 (GLOBE NEWSWIRE) -- April 16, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a...

Loughborough, England, March 28, 2019 (GLOBE NEWSWIRE) -- Loughborough, England – March 28, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of...